Programmatic Evaluation of a Combined Antigen and Antibody Test for Rapid HIV Diagnosis in a Community and Sexual Health Clinic Screening Programme by Taegtmeyer, Miriam et al.
Programmatic Evaluation of a Combined Antigen and
Antibody Test for Rapid HIV Diagnosis in a Community
and Sexual Health Clinic Screening Programme
Miriam Taegtmeyer1*, Peter MacPherson1,2, Kathy Jones3, Mark Hopkins4, Jay Moorcroft4, David G.
Lalloo1, Anu Chawla4
1 Liverpool School of Tropical Medicine, Liverpool, United Kingdom, 2Wellcome Trust Tropical Centre, University of Liverpool, Liverpool, United Kingdom, 3 The Liverpool
Centre for Sexual Health, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom, 4 Liverpool Specialist Virology Centre, Royal
Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom
Abstract
Background: A substantial proportion of HIV-infected individuals in the UK are unaware of their status and late
presentations continue, especially in low prevalence areas. Fourth generation antigen/antibody rapid test kits could
facilitate earlier diagnosis of HIV in non-clinical settings but lack data on performance under programmatic conditions.
Methods and Findings: We evaluated the performance of Determine HIV-1/2 Ag/Ab Combo Test (Determine Combo), a
rapid test with indicators for both HIV antibodies and p24 antigen, in participants recruited from community outreach and
hospital-based sexual health clinics. HIV infection was confirmed using laboratory enzyme-linked immunosorbent assay
(EIA), Line Immuno Assay (LIA) and quantitative polymerase chain reaction (PCR). In total, 953 people underwent HIV testing.
HIV antibody (Ab) prevalence was 1.8% (17/953). Four false positive rapid tests were identified: two antibody and two p24
antigen (Ag) reactions. Of participants diagnosed as HIV Ab positive, 2/17 (12%) were recent seroconverters based on
clinical history and HIV antibody avidity test results. However, none of these were detected by the p24 antigen component
of the rapid test kit. There were no other true positive p24 Ag tests.
Conclusion: These data lend support to an increasing body of evidence suggesting that 4th generation rapid HIV tests have
little additional benefit over 3rd generation HIV kits for routine screening in low prevalence settings and have high rates of
false positives. In order to optimally combine community-based case-finding among hard-to-reach groups with reliable and
early diagnosis 3rd generation kits should be primarily used with laboratory testing of individuals thought to be at risk of
acute HIV infection. A more reliable point of care diagnostic is required for the accurate detection of acute HIV infection
under programmatic conditions.
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Introduction
Fourth generation HIV antibody-antigen combination tests are
increasingly used in UK laboratory settings to ensure reliable
laboratory diagnosis of acute HIV infection, since the antibody
may not be detected during the so-called ‘‘seroconversion window
period’’ [1,2]. Simple rapid point of care HIV antibody tests are
well established in voluntary counselling and testing (VCT) centres
globally [3] and increasingly used in community settings in UK
[4,5]. However, there is little field data on the additional benefit of
p24 antigen rapid tests in community programmes. With the
global scale up of the use of rapid tests, reliable point of care
detection of acute HIV infection in non-laboratory settings may
have additional public health benefits in identifying acute infection
earlier [6].
Kit manufacturers have developed a 4th generation point of
care antigen/antibody kit (Determine HIV 1/2 Ag/Ab Combo;
Alere). This has performed well in published data against known
panels of seroconverters [7] with the p24 antigen detection
preceding the development of antibody, by an average of 5 to 9
day [8]. However, it has performed less well in field evaluations in
London [9] and Malawi [10] with both reporting a low sensitivity
for the p24 component.
Case-finding of individuals with recent HIV infection is an
important clinical and public health intervention [6]. Acute HIV
infection is under-recognised with, in one UK study, approxi-
mately half of patients experiencing non-specific symptoms of HIV
seroconversion and attending primary care or emergency
departments failing to be diagnosed [11]. The inclusion of p24
antigen on rapid HIV test kits leads to a shortening of the
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diagnostic window period and the ease of use of these kits could
lead to a greater detection of acute infection in clinical and
community sites where a seroconversion illness may have
otherwise been missed.
Liverpool has a low prevalence of HIV infection [12] but
continues to have a significant number of late presentations, with
an estimated one-third of HIV positive individuals undetected in
the community [13]. Presentations of acute HIV infection to
clinicians often go unrecognised [14]. Neither the hospital-based
sexual health clinic nor the existing outreach and community
programmes were offering point of care HIV testing before this
study. We set out to evaluate the utility of fourth generation HIV
tests under programmatic conditions in such settings and to make
recommendations for policy makers.
Methods
We offered rapid HIV testing with Determine HIV 1/2 Ag/Ab
Combo to individuals seeking care at a variety of existing
community services for intravenous drug users (IVDUs), men
who have sex with men (MSM), asylum seekers and sex workers, as
well as communities of UK Africans through church groups. In
addition, The Liverpool Centre for Sexual Health, a hospital
genitourinary medicine (GUM) clinic, conducted testing for
outpatient clinic attendees.
Our target group for HIV testing included individuals who felt
they may have been at- risk of HIV. However, we recognised that
all participants may not have had similar levels of HIV risk
behaviour. Therefore, participants who self-identified themselves
as any of the following groups were classified as being ‘‘high-risk’’:
MSM; current or previous history of IVDU; originating from a
high prevalence country; having bought or sold sex; reported
being raped; or having an HIV-positive partner. Presumed acute
HIV infection was defined as a participant who had laboratory
confirmed HIV infection; and had a documented negative
laboratory HIV test at our centre within three months prior to
undergoing rapid HIV testing in the study; and had a clinical
history consistent with risk exposure in the previous three months.
Based on the World Health Organization’s recommendations
for rapid HIV testing programmes, a serial testing algorithm was
used [15]. Testing was conducted according to manufacturer’s
instructions by trained nurses and health care assistants already
employed in community outreach or GUM settings. Training and
certification of competency was done by the virology laboratory
against a panel of known sera. The laboratory also provided
samples to the sites for regular internal and external quality
assurance including a 6-monthly blinded proficiency panel. Test
results were recorded on a standardised register in all sites and
visually verified by a second reader before being discarded. Tests
were deemed ‘‘invalid’’ if the control line failed to appear by the
end of the read time as stipulated in the manufacturer’s
instructions.
Invalid rapid tests that failed to resolve on immediate retesting
and all reactive rapid tests had a venous sample sent to the
laboratory for confirmatory testing. Antibody reactive tests or
invalid rapid tests were retested using a confirmatory fourth-
generation EIA followed by another confirmatory test Line
Immuno assay (LIA, Inno-Lia HIV-1/HIV-2 Ab Innogenetics,
Belgium). P24 antigen reactive rapid tests were additionally
retested in the laboratory using two separate RNA viral load
Cobas TaqMan HIV-1 Test, (Roche Diagnostics, UK) measure-
ments a week apart. Detailed risk histories and any previous stored
samples from the same individuals (when available) were reviewed
for all participants with reactive or invalid results on point of care
testing. Samples from individuals meeting our clinical criteria for
seroconversion were also tested by HIV antibody avidity assay
subject to availability of sample with a low avidity index being
considered consistent with recent infection [16].
Ethical approval was obtained from the institutional review
boards of Liverpool School of Tropical Medicine, NHS Sefton and
Cheshire Research Ethics Committee Liverpool and the Royal
Liverpool University and Broadgreen Hospitals Trust. Informed
verbal consent for HIV testing was obtained from all participants
and recorded in participant’s clinical notes at the GUM clinic and
in study logbooks at community-based sites. Written consent was
not required by the research ethic committees as this study
undertook post-marketing assessment of test kit performance. The
institutional review boards approved the verbal consent proce-
dures for HIV testing. All participants diagnosed HIV positive
were referred for comprehensive HIV care (including assessment
for antiretroviral therapy) at the genitourinary medicine clinic at
the Royal Liverpool and Broadgreen Hospital.
Results
Data from 953 individuals tested in nine months, from
September 2009 to July 2010, were included in this analysis.
More men (659/946, 69.7%) than women (287/946, 30.3%) were
tested and the median age was 29 years (interquartile range (IQR):
23–38 years). Approximately 70% (435/641) were white British.
Complete self-reported risk data were available on 927/953
(97.3%). In total, 517/927 (55.7%) had one or more behaviours
identified that may have put them at ‘‘high-risk’’ of HIV (Table 1):
133/926 (14.4%) originated from a high prevalence country; 264/
931 (28.4%) self- identified as men who have sex with men;
intravenous drug use was identified as a risk in 82/927 (8.6%); 38/
927 (4.1%) had bought or sold sex; 28/927 (3.0%) people
requested testing because they had an HIV positive partner; and
18/927 (1.9%) after being raped.
Seventeen new cases of HIV were detected, 16 among ‘‘high-
risk’’ individuals and one had no identified high-risk exposure by
our definition (Figure 1). An additional two antibody reactive tests
were found to be false positives following laboratory EIA. Two
further individuals were reactive to p24 antigen only and
laboratory testing following the algorithm described above did
not confirm HIV infection in either case. The overall HIV-
prevalence in the study population was 1.8% (17/953) and was
3.1% (16/517) in ‘‘high-risk’’ individuals. The overall positive
predictive value of a reactive rapid test in comparison to the
laboratory gold standard was 80.9%. Confirmed HIV-positive
individuals had a median CD4 count at diagnosis of 315 cells/ul
(interquartile range [IQR]: 220–377).
Sixteen of 953 point of care tests (1.7%) were invalid on first
rapid test. Two of these were reactive on immediate retesting and
both were confirmed positive on laboratory testing. Six were non-
reactive on immediate retesting and no further sample was sent.
The remaining eight were EIA negative on laboratory retesting.
Of the seventeen confirmed HIV-positive participants, two (12%)
met our clinical definition for presumed recent HIV infection.
Both also had a low HIV avidity index [16] consistent with recent
infection (indices of 40% and 74% respectively). However, both
were p24 antigen negative on rapid testing.
Discussion
We describe results from a joint community and clinic-based
programme using fourth generation rapid HIV tests. Screening
was targeted towards at-risk individuals in a low prevalence setting
and was able to identify new cases of HIV antibody positivity in
Programmatic Evaluation of an Ab/Ag Rapid HIV Test
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e28019
3% of those who self-reported themselves to be at ‘‘high-risk’’.
Near- patient tests performed in clinical and non-clinical settings
offered the opportunity to increase availability of testing for hard-
to-reach groups and allowed for rapid results [4]. We took the
opportunity presented by rapid testing to incorporate prevention
messages [17] and facilitate earlier access to care for those
diagnosed positive [18].
Early diagnosis of HIV is recognized as an important public
health intervention, with recent studies showing that a strategy of
high population uptake of HIV testing linked to immediate
initiation of ART could dramatically reduce HIV transmission and
mortality in high prevalence settings [19]. In sub-Saharan Africa,
HIV testing strategies include a broad mix of programmes,
including voluntary counselling and testing (VCT), provider
initiated testing (PITC) within health facilities, door-to-door
testing and supervised self-testing in communities [20,21].
However, in low HIV prevalence countries, programmes have
lagged somewhat behind with particular shortcomings in identi-
fying recently infected individuals [11]. New recommendations
from the British HIV Association [22] and the Centers for Disease
Control [23] have attempted to address this by recommending
increased availability to HIV testing in non-clinical facilities and
using novel technologies. Fourth generation rapid test kits have
been suggested as an important tool in these strategies to increased
the public health impact of HIV testing programmes by allowing
early diagnosis and intervention in acute infection, and by
facilitating decentralization of testing services into communities
[21]. However, we identified a number of current limitations to
their implementation.
In our programme both p24 antigen positive reactions were
false positives and none of the two individuals presumed to have
acute HIV infection were detected by p24 antigen. A previous
study reporting performance of fourth generation rapid HIV test
kits in community-based sites working with men who have sex with
men in San Francisco reported a high sensitivity of 96% and
specificity of 100% of the p24 component of Determine 4th
generation [24]. These findings were neither borne out in our
study nor in recent studies in Malawi [10] and the UK [9]. In
Malawi, which is a higher HIV prevalence setting than ours, 846
individuals were tested in parallel with Determine 1/2 and found
to be either HIV negative or serodiscordant on initial screening,
the p24 portion of the Combo rapid test was falsely negative in all
8 acute HIV infections identified and there were 14 false positive
p24 antigen tests [10]. Similarly, in the UK study, 62% of
laboratory confirmed acute HIV infections were detected by the
p24 component of Determine [9].
As in these studies, we found little advantage to the inclusion of
p24 antigen and identified a number of disadvantages to the use of
fourth generation antigen/antibody rapid test kits in community-
based settings. Firstly, false positive diagnoses of seroconversion
are likely to be high, particularly in low prevalence settings and
could create a significant problem with point of care use of this
assay, generating considerable anxiety for clients and lead to
increased unnecessary loads on laboratories. Secondly, 1.7% of the
tests we performed were invalid according to manufacturer’s
instructions. In almost all cases, we observed that the buffer failed
to travel as far as the control line within the read time window.
Invalid tests were observed throughout the study period and not
confined to the first few weeks after training. This may be a factor
of the additional length of strip used to accommodate the p24
strip. Finally, even those individuals identified by us as having
recent HIV infection were already antibody reactive and p24 non-
reactive on the rapid test when assessed, indicating that the
additional value of the p24 component may be restricted to the
first few days after transmission of the virus – a phenomenon that
is well recognised elsewhere [25].
The main limitation of this programmatic evaluation is that only
participants who had reactive or invalid point of care tests had
laboratory samples analyzed. This means that we were unable to
calculate the sensitivity, specificity and negative predictive value of
the 4th generation POCT kit. Despite this, we feel that it is
valuable to present our findings as new fourth generation rapid
tests are developed and piloted under programmatic conditions
and future studies will be required to undertaken these evaluations.
Secondly; our case definition of presumed recent HIV infection
was primarily clinical. It included assessment of recent high-risk
behavior from review of clinical notes and review of previous
negative laboratory HIV testing results. HIV antibody avidity
assays only became part of routine clinical practice in UK in the
course of 2010 and as a result only 7 out of 17 newly diagnosed
patients had samples referred for this test. Both patients meeting
our clinical definition were confirmed as recent infections by
confirmatory avidity testing. It is therefore possible that the
prevalence of recent ‘‘high-risk’’ behavior may have been
Table 1. Baseline characteristics and reported risk exposure of participants.
Characteristic N (%)1
Male 659/946 (69.7)
Median Age (IQR) 29 (23–38)
Any identified high risk factor* 517/927 (55.8%)
Risk summary categories (Not mutually exclusive: one case can be represented in multiple categories)
UK African 133/927 (14.3%)
Intravenous drug user 82/927 (8.8%)
MSM 264/927 (28.5%)
CSW 38/927 (4.1%)
HIV-positive partner 28/927 (3.0%)
Reported rape 18/927 (1.9%)
*43 participants had more than one identified risk factors.
1Denominator varies due to missing data in some categories.
MSM: men-who-have-sex-with-men CSW: commercial sex work (bought or sold sex).
doi:10.1371/journal.pone.0028019.t001
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underestimated, meaning that some participants with confirmed
infection may have not have been classified as having recent
infection. Further, although we were able to access previous
negative HIV test results in clinical files and from laboratory
records, participants may have recently tested negative elsewhere.
We have found that community-based fourth generation HIV
testing in low HIV prevalence settings may have limited additional
benefit over programmes using third generation antibody only kits.
In order to reach a balance between providing reliable and early
diagnosis of HIV in the community and targeting testing
programmes to hard-to-reach groups, we suggest a combined
approach of outreach testing using third generation test kits with
back up fourth generation laboratory-based EIA for individuals
suspected to have acute HIV infection.
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